H2 receptor Inhibitors
1 drugsAbout H2 receptor
The histamine H2 receptor regulates gastric acid secretion in the stomach. Its physiological function makes it a relevant target for pharmaceutical intervention.
Currently, there is no genetic evidence data available linking the H2 receptor to specific diseases, limiting confidence in target validation.
One FDA-approved drug, Famotidine Preservative Free (Hikma), targets the H2 receptor. It is a small molecule approved in 2001 for 7 indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Multiple Myeloma with only 1 trials.
Top H2 receptor Drugs
Hikma is the only company with an approved drug targeting H2 receptor.
Low competition suggests an opportunity for new entrants, but also a potentially limited market.
H2 receptor Clinical Trials 84 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 43 | 34 | 5 | 4 | 87% |
| Phase 2 | 19 | 10 | 5 | 4 | 67% |
| Phase 3 | 7 | 4 | 2 | 1 | 67% |
| Phase 4 | 15 | 8 | 3 | 3 | 73% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 79 clinical trials targeting H2 receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities